Why Organon (OGN) Is Surging as Buyout Interest Gains Traction

Organon & Co. (NYSE:OGN) is one of the 10 potential takeover targets with strong price momentum. Around April 10–13, 2026, reports emerged that Sun Pharmaceutical Industries had submitted a binding offer to acquire the company in a deal valued at roughly $10 billion to $12 billion. The market reaction was immediate.

Organon shares surged about 28% in a single session and had risen nearly 39% over the week following the reports, marking one of the sharpest moves tied to takeover speculation this year.

Why Organon (OGN) Is Surging as Buyout Interest Gains Traction

pathdoc/Shutterstock.com

That reaction reflects how the market is pricing in the strategic value of the business rather than its current financial profile. Organon, which was spun off from Merck & Co. in 2021, has a portfolio spanning women’s health, biosimilars, and established medicines, including contraceptive and fertility products such as Nexplanon and NuvaRing. The company’s scale and product base make it a plausible target for a strategic buyer looking to expand internationally or deepen exposure to women’s health.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on women’s health, biosimilars, and a portfolio of established medicines.

While we acknowledge the risk and potential of OGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.